EON RETURN ON INVESTMENT
A single identified pulmonary nodule brings on average $3,491 in revenue for a hospital with an estimated contribution margin of $1,326. The financial impact of the COVID-19 Pandemic on hospitals has already rippled across the country as patient care has been deferred or delayed. Yet, the business of identifying, managing, and treating patients with pulmonary lung nodules remains essential for patient outcomes and for the financial health of hospitals.
As hospitals ramp up after the pandemic’s surge, identifying, managing, and treating pulmonary nodule patients at high risk for diagnosis of lung cancer has never been more critical. Processing the immense backlog of patients requires unprecedented scale to optimize restricted resources to treat and monitor all essential patients.
The Return On Investment (ROI) Model for Essential Patient SafetyNet projects a yearly revenue of over $785,000 from downstream patient capture associated with reviewing 1,000 Chest CTs and 100 LDCT reports analyzed by EonEndu.
With an investment of $19,750 in the best in class computational linguistic software, SafetyNet identifies an equivalent revenue stream in less than 25 days after activation with a modest capture rate. A cumulative contribution margin of over $298,000 for the first year takes into account the cost of the software, as well as other administrative, operating, and overhead costs associated with running a Thoracic Oncology Service Line — costs that may already be incurred but with a lower return.
The Model projects yearly revenue increases to $1.2 million with Eon’s Essential Patient Management Program, and $1.7 million with Eon’s Centralized Management offerings using the same 1,000 Chest CTs and 100 LDCT reports analyzed by EonEndu. With enhanced management of patient capture, identified critical cases translate into more effective downstream revenue. With a marginally higher cost ($36,550 and $51,625, respectively), hospitals see hundreds of thousands of dollars more in the cumulative contribution margin by the end of the first year – $447,525 and $671,287 more respectively in the first year.
Eon estimates that the revenue per patient with a nodule identified is $3,491 with a base contribution margin of $1,326 once patient management and treatment costs are accounted for, based on true data from early-stage Eon customers with a similar SafetyNet solution. This is the projected average revenue for an identified nodule, which takes into account non-adherence and an average distribution of surveillance and diagnostic treatment projections within the identified population. While this revenue will not be captured on day one of identification, the reliable revenue stream will be captured by a hospital within the lifecycle of patient treatment.
Eon estimates this revenue increases to $5,236 and the contribution margin rises to $1,989 with the increased capture capability of Eon’s Essential Patient Management Software. Being able to more efficiently identify and manage critical populations yields better adherence rates and captured revenue for patients that would otherwise be untreated and unmonitored.
Eon implements best practices from across the industry in the Centralized Management Program. This implementation results in even greater adherence and capture rates, pushing the revenue per patient identified to $7,854 and cumulative margin to $2,984.
With a 20% identification rate for nodules identified on Chest CT’s analyzed by EonEndu and a 25% identification rate on LDCT, hospitals can expect to break even on the yearly cost of SafetyNet, EPM, or Centralized Management early in the year when considering future revenue for these identified patients.
A cost breakdown of Eon’s SafetyNet, Essential Patient Management, and Centralized Management programs can be requested by contacting us at firstname.lastname@example.org